Citadel Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.32M | Buy |
6,596
+4,530
| +219% | +$896K | ﹤0.01% | 7037 |
|
|
2025
Q4 | $391K | Sell |
2,066
-11,246
| -84% | -$2.16M | ﹤0.01% | 9589 |
|
|
2025
Q3 | $2.36M | Sell |
13,312
-28,594
| -68% | -$4.25M | ﹤0.01% | 5732 |
|
|
2025
Q2 | $4.76M | Buy |
+41,906
| New | +$4.48M | ﹤0.01% | 4192 |
|
|
2024
Q4 | – | Sell |
-23,814
| Closed | -$2.69M | – | 15002 |
|
|
2024
Q3 | $2.38M | Sell |
23,814
-21,996
| -48% | -$2.21M | ﹤0.01% | 5198 |
|
|
2024
Q2 | $3.86M | Sell |
45,810
-3,754
| -8% | -$299K | ﹤0.01% | 4159 |
|
|
2024
Q1 | $3.62M | Buy |
49,564
+39,762
| +406% | +$2.93M | ﹤0.01% | 4479 |
|
|
2023
Q4 | $700K | Sell |
9,802
-22,301
| -69% | -$1.32M | ﹤0.01% | 7399 |
|
|
2023
Q3 | $1.92M | Buy |
32,103
+29,241
| +1,022% | +$1.92M | ﹤0.01% | 5289 |
|
|
2023
Q2 | $206K | Sell |
2,862
-69,995
| -96% | -$5.25M | ﹤0.01% | 9818 |
|
|
2023
Q1 | $5.36M | Sell |
72,857
-80,071
| -52% | -$5.69M | ﹤0.01% | 3696 |
|
|
2022
Q4 | $10.2M | Buy |
152,928
+117,713
| +334% | +$7.65M | ﹤0.01% | 2808 |
|
|
2022
Q3 | $1.89M | Buy |
+35,215
| New | +$2.07M | ﹤0.01% | 5693 |
|
|
2022
Q2 | – | Sell |
-2,982
| Closed | -$169K | – | 13566 |
|
|
2022
Q1 | $209K | Sell |
2,982
-2,178
| -42% | -$158K | ﹤0.01% | 11431 |
|
|
2021
Q4 | $497K | Sell |
5,160
-16,642
| -76% | -$1.54M | ﹤0.01% | 9709 |
|
|
2021
Q3 | $1.89M | Buy |
21,802
+10,167
| +87% | +$786K | ﹤0.01% | 6501 |
|
|
2021
Q2 | $952K | Sell |
11,635
-2,505
| -18% | -$208K | ﹤0.01% | 8492 |
|
|
2021
Q1 | $1.34M | Sell |
14,140
-142,972
| -91% | -$13.5M | ﹤0.01% | 7374 |
|
|
2020
Q4 | $9.75M | Sell |
157,112
-206,028
| -57% | -$11.7M | ﹤0.01% | 2666 |
|
|
2020
Q3 | $21.6M | Buy |
363,140
+228,525
| +170% | +$15.6M | 0.01% | 1508 |
|
|
2020
Q2 | $9.39M | Sell |
134,615
-169,682
| -56% | -$10.8M | ﹤0.01% | 2296 |
|
|
2020
Q1 | $13.8M | Buy |
304,297
+106,985
| +54% | +$6.06M | 0.01% | 1546 |
|
|
2019
Q4 | $12.8M | Sell |
197,312
-601
| -0.3% | -$40.2K | 0.01% | 1943 |
|
|
2019
Q3 | $12.3M | Buy |
197,913
+79,115
| +67% | +$4.97M | 0.01% | 1985 |
|
|
2019
Q2 | $8.46M | Sell |
118,798
-51,359
| -30% | -$3.78M | ﹤0.01% | 2381 |
|
|
2019
Q1 | $13.3M | Buy |
170,157
+79,280
| +87% | +$6.01M | 0.01% | 1733 |
|
|
2018
Q4 | $7.69M | Buy |
90,877
+86,756
| +2,105% | +$9.25M | ﹤0.01% | 2206 |
|
|
2018
Q3 | $706K | Sell |
4,121
-14,346
| -78% | -$2.16M | ﹤0.01% | 6148 |
|
|
2018
Q2 | $2.39M | Buy |
18,467
+16,200
| +715% | +$1.81M | ﹤0.01% | 3825 |
|
|
2018
Q1 | $234K | Sell |
2,267
-1,648
| -42% | -$163K | ﹤0.01% | 7102 |
|
|
2017
Q4 | $334K | Sell |
3,915
-2,148
| -35% | -$186K | ﹤0.01% | 6283 |
|
|
2017
Q3 | $515K | Buy |
+6,063
| New | +$480K | ﹤0.01% | 5277 |
|
|
2017
Q1 | – | Sell |
-3,312
| Closed | -$218K | – | 7781 |
|
|
2016
Q4 | $210K | Sell |
3,312
-2,688
| -45% | -$170K | ﹤0.01% | 6243 |
|
|
2016
Q3 | $382K | Buy |
+6,000
| New | +$441K | ﹤0.01% | 5274 |
|
|
2016
Q1 | – | Sell |
-3,054
| Closed | -$186K | – | 7423 |
|
|
2015
Q4 | $207K | Buy |
+3,054
| New | +$189K | ﹤0.01% | 5765 |
|
|
2015
Q3 | – | Sell |
-4,399
| Closed | -$267K | – | 9074 |
|
|
2015
Q2 | $277K | Sell |
4,399
-1,237
| -22% | -$67.5K | ﹤0.01% | 5868 |
|
|
2015
Q1 | $271K | Sell |
5,636
-1,719
| -23% | -$65.9K | ﹤0.01% | 5794 |
|
|
2014
Q4 | $244K | Buy |
7,355
+2,540
| +53% | +$82.6K | ﹤0.01% | 5726 |
|
|
2014
Q3 | $141K | Buy |
4,815
+343
| +8% | +$11.4K | ﹤0.01% | 6070 |
|
|
2014
Q2 | $174K | Sell |
4,472
-46,119
| -91% | -$1.87M | ﹤0.01% | 5710 |
|
|
2014
Q1 | $2.12M | Buy |
50,591
+43,062
| +572% | +$1.79M | ﹤0.01% | 2596 |
|
|
2013
Q4 | $247K | Sell |
7,529
-55,605
| -88% | -$1.81M | ﹤0.01% | 4806 |
|
|
2013
Q3 | $1.7M | Buy |
+63,134
| New | +$1.78M | ﹤0.01% | 2566 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Citadel Advisors's LGND Position: Q1 2026 in Review
Citadel Advisors increased its Ligand Pharmaceuticals (LGND) stake by 219% in Q1 2026, buying an estimated $896K and bringing the position to 6,596 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7037.
Citadel Advisors first reported a position in LGND in Q3 2013 and has held it in 43 quarters since. The position peaked at $21.6M in Q3 2020. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Citadel Advisors held 6,596 shares of Ligand Pharmaceuticals worth $1.32M as of Q1 2026.
- Citadel Advisors bought 4,530 Ligand Pharmaceuticals shares in Q1 2026, an estimated $896K.
- Ligand Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7037 holding.
- Citadel Advisors first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- Citadel Advisors's Ligand Pharmaceuticals position peaked at $21.6M in Q3 2020.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.